Zimmer Biomet’s Mymobility Study: Fresh Clinical Data on a Digital Edge in Joint Replacement
Zimmer Biomet Holdings (ZBH) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The study, titled “A Prospective Multicenter Longitudinal Cohort Study of the Mymobility Platform,” looks at whether Zimmer Biomet’s mymobility with Apple Watch can match or improve on standard physical therapy after hip and knee replacement. It matters because better remote rehab could lower costs and support wider use of ZBH’s digital tools.
The main treatment is the mymobility mobile app used with Apple Watch. It gives patients simple education, exercise plans and activity tracking after surgery, aiming to guide rehab at home and cut the need for in‑person therapy.
The trial is interventional and runs across several centers. Patients are split into groups, with about 1,000 in a randomized head‑to‑head comparison of mymobility versus usual physical therapy, and there is no blinding, so both patients and doctors know which care they receive.
The primary goal is supportive care, not drug testing. The key measure is how many patients are readmitted within 30 days of surgery, along with pain, function, balance, satisfaction and urgent care use over 90 days, to show whether app‑based rehab is as safe and effective as usual care.
The study was first submitted on 2018‑10‑26, highlighting an early move by ZBH into digital orthopedics. The most recent update on 2026‑03‑20, along with posted primary and secondary outcomes, signals that the trial is complete and data have been analyzed and entered into the ClinicalTrials system.
While the official status is listed as completed, the 2026 update and posted outcomes keep the study current for investors who track clinical evidence. These timestamps help the market see ZBH’s digital platform as clinically validated rather than just a tech concept.
For Zimmer Biomet (ZBH), positive data on lower readmissions or similar outcomes versus standard therapy could support higher surgeon adoption and stronger pricing power for its mymobility ecosystem. It would also strengthen the company’s broader narrative around value‑based care and post‑acute cost savings.
If payers and hospitals see that app‑based rehab can safely replace some in‑person visits, that may boost demand for ZBH implants bundled with digital services. Over time, this can create stickier customer relationships and recurring revenue from software and data tools, beyond the one‑time sale of an implant.
Competitors like Stryker and Johnson & Johnson are also investing in smart implants and digital monitoring, so the mymobility study helps ZBH defend and possibly grow its share in connected orthopedics. Strong outcomes could push peers to accelerate their own digital offerings, raising the bar for standard care across the sector.
Near term, the market impact will depend on how clearly ZBH ties these clinical results to reduced complications, lower readmissions and fewer emergency visits. Investors should watch upcoming earnings calls and strategy updates for signals that large health systems are signing on to integrate mymobility into routine joint replacement pathways.
Overall, this completed and recently updated study supports the view that digital rehab will be a key growth driver in orthopedics, and it helps de‑risk ZBH’s spend on the mymobility platform. The study is completed and remains updated in the registry, with more details available on the ClinicalTrials portal.
